Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection Fraction
about
Introduction to Cardiovascular Magnetic Resonance: Technical Principles and Clinical ApplicationsThe role of titin and extracellular matrix remodelling in heart failure with preserved ejection fractionUnderstanding heart failure with preserved ejection fraction: where are we today?Left ventricular function assessment in cirrhosis: Current methods and future directions.Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone.Myocardial Regional Interstitial Fibrosis is Associated With Left Intra-Ventricular Dyssynchrony in Patients With Heart Failure: A Cardiovascular Magnetic Resonance Study.Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone.Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study.Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular PerformancePulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fractionCirculating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy.Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis.Gadolinium free cardiovascular magnetic resonance with 2-point Cine balanced steady state free precession.Presence of ´isolated´ tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fractionCardiac MRI: a central prognostic tool in myocardial fibrosis.T1 mapping: non-invasive evaluation of myocardial tissue composition by cardiovascular magnetic resonance.The (dys)functional extracellular matrix.PET/MR: Yet another Tesla?Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis.Electrocardiographic Impact of Myocardial Diffuse Fibrosis and Scar: MESA (Multi-Ethnic Study of Atherosclerosis).Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction.Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction.Myocardial Native T1 Time in Patients With Hypertrophic Cardiomyopathy.Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T.Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for CardiovascularSeeing the unseen fibrosis in heart failure with preserved ejection fraction.Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis.Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy.Comparison of MOLLI, shMOLLLI, and SASHA in discrimination between health and disease and relationship with histologically derived collagen volume fraction.Extracellular volume quantification by cardiac magnetic resonance imaging without hematocrit sampling : Ready for prime time?Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.Wedge Pressure Rather Than Left Ventricular End-Diastolic Pressure Predicts Outcome in Heart Failure With Preserved Ejection Fraction.Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.The evaluation of non-ischemic dilated cardiomyopathy with T1 mapping and ECV methods using 3T cardiac MRI.Diffuse myocardial fibrosis among healthy pediatric heart transplant recipients: Correlation of histology, cardiovascular magnetic resonance, and clinical phenotype.Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction.The Emerging Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Patients with HFpEF.Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure.Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping.
P2860
Q26749269-DC5D8950-E387-486F-9918-4A859A8C38BBQ26765101-2E1C265D-C959-46C4-A9B2-564EDA9805E2Q26766590-43DFC33F-B53D-457F-A487-2DF8ECE44DA9Q26769598-D5C96A1E-DE03-4F38-8A2F-460C8D489E95Q30300980-FE1999FA-E64F-49E8-A565-FF962CCFA402Q30391425-50183146-0EA7-4CF5-9199-DE147A6EB577Q30833375-0B19290D-9A1E-47D8-801D-A24CC3C3241AQ34374909-DEF75C75-4056-49B5-9862-D9C1FCA22FADQ35725839-32D1DB1C-147E-41D4-B3D4-529C69AAED93Q36006309-30F52FBD-ED93-4F2A-97D8-E0F8D49A0405Q36088154-2CE500DB-B2E7-4FAF-BC24-7CAB15FD0B0AQ36220925-BAA146F3-E500-4077-BA50-B2B7C270DF87Q36235217-A0EF4EAF-F7EF-4017-A9AD-66BE242BC407Q36281115-862636B4-13D0-4D34-96E8-6215DCB953BCQ38263089-9B35B2C6-759C-4DBB-8501-E1F2076BE542Q38270769-314A5B29-571F-42C7-88B3-23DCCD35EE23Q38452473-9F1FCE1B-BA78-4F1A-9693-B0DB8C2A12CCQ38818563-D506734C-FCF1-41AA-B60A-A434561F9938Q38959952-D47A7301-AD13-46B6-889C-8F5327EFD01BQ38980504-58B46963-7499-493E-A7F8-0229B9219814Q40149965-2186C1B3-911E-4BD8-8EDC-FBC05E8A0901Q40963394-93A73560-3794-47C0-96D6-BB85F11DE4F6Q41629593-0473A653-1810-4F3E-9296-F59C0632B0E5Q42089705-99784637-77A1-4CE1-82AB-94F82CF7AF54Q42373017-E12FB3CE-5859-419B-A476-BFE9AE8F4B86Q42560934-DD27C55A-877A-4767-B0DA-2B205024C768Q45921977-4B663426-C2C1-464E-841D-FA3989C1DCC5Q47152878-19BA65E2-1153-4497-85FC-CA6C6FC6642DQ47297387-16BFCD90-9F39-4F7A-85CC-3AFAF3EDA67AQ47619369-179D5E9D-32C8-482F-82A5-E4A95E173872Q47755913-86BE6A95-F2A0-43E1-A25F-F8CBE7C14455Q47794661-DB37EEA3-0556-4F9D-9B4A-D031CFAD492AQ47890686-C476B71B-9C2D-4E7C-82C1-26A9A5DA9D42Q48271337-7A6D9807-FEEA-4F5F-92D4-939E0E569BF6Q48337289-D54505C8-D648-445D-8068-0CCF9E17E751Q50099011-154CEF6F-2DF1-4112-866F-77A2556243C1Q50193228-5400DA4C-5FB2-4B4F-B3CD-3482C8FEEFA0Q52819862-9158F2AC-4609-4701-A391-CDBB6ADC2CF0Q55494001-D08E2519-C309-4C13-B22C-9476C1E4DAFA
P2860
Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection Fraction
description
im November 2013 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 13 September 2013
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2013
@uk
name
Cardiac Magnetic Resonance Pos ...... nd Preserved Ejection Fraction
@en
Cardiac Magnetic Resonance Pos ...... nd Preserved Ejection Fraction
@nl
type
label
Cardiac Magnetic Resonance Pos ...... nd Preserved Ejection Fraction
@en
Cardiac Magnetic Resonance Pos ...... nd Preserved Ejection Fraction
@nl
prefLabel
Cardiac Magnetic Resonance Pos ...... nd Preserved Ejection Fraction
@en
Cardiac Magnetic Resonance Pos ...... nd Preserved Ejection Fraction
@nl
P2093
P50
P1476
Cardiac magnetic resonance pos ...... nd preserved ejection fraction
@en
P2093
Adelheid Panzenböck
Beatrice A Marzluf
Caroline Tufaro
Christine Bangert
Daniela Laimer
Diana Bonderman
Gültekin Karakus
Irene M Lang
Martin Hülsmann
Paul Wexberg
P304
P356
10.1161/CIRCIMAGING.113.000633
P577
2013-09-13T00:00:00Z